Replies to post #278875 on Avid Bioservices Inc (CDMO)

[jakedogman1]

another way to look at your ten step plan is put the entire platform in capable hands with enough money to get them out of the doghouse and focus on avid...

imo they can't do the ten step plan and focus on avid at the same time because of lack resources... and their credibility on trials is shot... and the window is now... not twelve months from now... hopefully they know that...

if they can continue to build avid and keep the incestuous bod "as is" without oversight and fiduciary responsibility they will have access to a cash flow machine without any interference from pesky shareholders... keep in mind their management has been all about them and keeping control without oversight and accountability...

if they were contemplating your plan, the hiring picture would be different imo...

the one thing shareholders can agree on is hoping this nightmare will end soon...

let's communicate friday at happy hr... some birds are singing...

[aikifredicist]

If I recall correctly Peregrine planed the subverted Phase II trial with 1 mg and 3 mg arms. At that time they stated that according to their calculations the 1 mg dosage should suffice. After the Fargo disaster, they stuck with the 3 mg for Sunrise. The Fargo 3 mg arm appeared to perform well. As you say perhaps too much Bavi and not enough B2-Gp1 will result in ineffectual one armed Bavi floating around depleting the B2-GP1. I find it still interesting that mch1N11 dosing does not seem to have that problem in the mouse model. The Sloan-Kettering people did not test for B2GP1 levels. I doubt if any of the other mouse tests looked at it either.

--- Umm.. I'm getting a headache.